COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Azathioprine in Recurrent Implantation Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03498703
Recruitment Status : Completed
First Posted : April 17, 2018
Last Update Posted : July 24, 2019
Capital Birth Center
Information provided by (Responsible Party):
Ahmed Reda, Ain Shams University

Brief Summary:
Azathioprine increase pregnancy rate in patients with recurrent implantation failure

Condition or disease Intervention/treatment Phase
Recurrent Implantation Failure In Vitro Fertilization Intracytoplsmic Sperm Injection Drug: Azathioprine Pill Drug: Placebo Oral Tablet Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Azathioprine in Recurrent Implantation Failure
Actual Study Start Date : April 25, 2018
Actual Primary Completion Date : July 1, 2019
Actual Study Completion Date : July 1, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Azathioprine Drug: Azathioprine Pill
Azathioprine increase pregnancy rate in cases with recurrent implantaion failure

Placebo Comparator: Control Drug: Placebo Oral Tablet
Placebo tablets

Primary Outcome Measures :
  1. Clinical pregnancy rate [ Time Frame: 2 weeks ]

Secondary Outcome Measures :
  1. Side effects [ Time Frame: 2 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 39 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • age: 20-39
  • previous 3 or more failed ivf

Exclusion Criteria:

  • intrauterine anomalies
  • chronic systemic illness
  • chronic pelvic conditions
  • sensitivety to azathioprine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03498703

Layout table for location information
Ain Shams University, Maternity Hospital
Cairo, Egypt
Capital Birth Center
Cairo, Egypt
Sponsors and Collaborators
Ain Shams University
Capital Birth Center
Layout table for investigator information
Study Director: Ahmed H Salama Capital Birth Center

Layout table for additonal information
Responsible Party: Ahmed Reda, Consultant, Ain Shams University Identifier: NCT03498703    
Other Study ID Numbers: FW000372
First Posted: April 17, 2018    Key Record Dates
Last Update Posted: July 24, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents